Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYP19A1 polymorphisms and letrozole response in postmenopausal hormone receptor-positive primary breast cancer
ChiCTR-RNC-12001942Phase 4Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of letrozole in breast cancer, sponsored by West China Hospital of Sichuan University. Primary endpoints: CYP19A1, Estradiol and 1 more. Started Jun 2012; status: completed.
02
Drugs
letrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR-RNC-12001942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-RNC-12001942.